Thomas Wooldridge, MD
Nephrology · Tupelo, MSNPI 1518937044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 417 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 417 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Travere Therapeutics, Inc.$952
- Fresenius USA Marketing, Inc.$892
- Otsuka America Pharmaceutical, Inc.$840
- Bayer$837
- Mallinckrodt Hospital Products Inc.$675
- plus $3K from 23 others
Across 313 payments — averaging $5214.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$670K
- GSK$383K
- CSL Behring$271K
- Akebia Therapeutics Inc$146K
- Otsuka Pharmaceutical Co., Ltd.$39K
- Alnylam Pharmaceuticals Inc.$31K
- plus $93K from 5 others
What the payments were for
- Food & beverage$8,11997%
- Education$2773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,295 |
| Travere Therapeutics, Inc. | 26 | $952 |
| Fresenius USA Marketing, Inc. | 47 | $892 |
| Otsuka America Pharmaceutical, Inc. | 41 | $840 |
| Bayer | 48 | $837 |
| Mallinckrodt Hospital Products Inc. | 32 | $675 |
| Akebia Therapeutics Inc | 23 | $415 |
| Vifor Pharma, Inc. | 21 | $374 |
| Novartis | 15 | $335 |
| Amgen | 18 | $324 |
| OPKO Pharmaceuticals, LLC | 18 | $288 |
| GSK | 7 | $188 |
| Daiichi Sankyo Inc. | 7 | $140 |
| Ardelyx, Inc. | 7 | $139 |
| Aurinia Pharma U.S., Inc. | 6 | $138 |
| ANI Pharmaceuticals, Inc. | 5 | $87 |
| Calliditas Therapeutics US Inc. | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 4 | $60 |
| Novo Nordisk | 4 | $56 |
| Boehringer Ingelheim | 3 | $47 |
| Mallinckrodt Enterprises LLC | 3 | $43 |
| Lilly USA, LLC | 2 | $34 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Baxter Healthcare | 1 | $25 |
| Renalytix AI, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
How this compares
$8,396 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 47 | $149,279 |
| AuryxiaFerric Citrate | 39 | $98,598 |
| FarxigaDapagliflozin Propanediol | 39 | $28,781 |
| KerendiaFinerenone | 34 | $21,407 |
| JardianceEmpagliflozin | 27 | $20,585 |
| OzempicSemaglutide | 11 | $15,653 |
| Sevelamer Carbonate | 90 | $13,341 |
| JanuviaSitagliptin Phosphate | 13 | $11,868 |
| Calcium Acetate | 49 | $3,259 |
| Torsemide | 215 | $2,771 |
| Potassium Citrate ErPotassium Citrate | 26 | $1,423 |
| Megestrol Acetate | 17 | $1,188 |
| Amlodipine Besylate | 215 | $940 |
| Losartan Potassium | 75 | $829 |
| Lisinopril | 108 | $812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $892 | $149,27947 claims |
| Akebia Therapeutics IncAuryxia | $415 | $98,59839 claims |
| AstraZenecaFarxiga | $1,295 | $28,78139 claims |
| BayerKerendia | $837 | $21,40734 claims |
| Boehringer IngelheimJardiance | $47 | $20,58527 claims |
| Novo NordiskOzempic | $56 | $15,65311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Tupelo
- John Martin LeeTupelo$6K
- Morris HamiltonTupelo$6K
- John ElliottTupelo$5K
- Christopher MillerTupelo$4K
- Tzonko MilevTupelo$4K
- Amita MaibamTupelo$4K
- Marcus BrittonTupelo$4K
- Calvin BakerTupelo$2K
- Shanti ParkashTupelo$2K
- Mohit AhujaFlowood$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.